CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,511,805 | +138.3% | 33,307 | +194.7% | 0.06% | +141.7% |
| Q2 2023 | $634,438 | -88.6% | 11,301 | -90.8% | 0.02% | -89.6% |
| Q1 2023 | $5,543,344 | +147.1% | 122,559 | +122.1% | 0.23% | +94.1% |
| Q4 2022 | $2,243,352 | +463.7% | 55,187 | +770.0% | 0.12% | +600.0% |
| Q1 2022 | $398,000 | +24.4% | 6,343 | +121.4% | 0.02% | -26.1% |
| Q3 2021 | $320,000 | -50.5% | 2,865 | -45.9% | 0.02% | -61.7% |
| Q1 2021 | $646,000 | – | 5,300 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |